Floatz logo

PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493

Stage II Bladder Cancer AJCC v8

National Cancer Institute (NCI)Small moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Stage II Bladder Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Atezolizumab
National Cancer Institute (NCI)
Phase 2BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2BB
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 2BB
Carboplatin
Iambic Therapeutics, Inc
Phase 2BB

View all 45 →

Same molecule, other indications

PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493 is also rated in:

neoplasmDormant
B
Indicative ·
60 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
lymphomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →